NEW YORK (GenomeWeb News) – The mergers and acquisitions market in the omics tools and molecular diagnostics space continues to be soft as the number of deals fell 11 percent year over year during the first half of 2013.

In the first half of the year, 24 deals were either completed or announced, down from 27 in the first half of 2012 and down from 28 from the second half of 2012. The figures include only those transactions in which the whole of a company was acquired. Not included were deals in which only divisions or assets exchanged hands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.